Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Pulmonx Corp (NASDAQ: LUNG) closed at $1.63 down -4.12% from its previous closing price of $1.7. In other words, the price has decreased by -$4.12 from its previous closing price. On the day, 0.68 million shares were traded. LUNG stock price reached its highest trading level at $1.715 during the session, while it also had its lowest trading level at $1.61.
Ratios:
For a deeper understanding of Pulmonx Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.15 and its Current Ratio is at 4.86. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.92.
On March 10, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $17.
Citigroup Downgraded its Buy to Neutral on December 11, 2024, whereas the target price for the stock was revised from $17 to $7.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 02 ’25 when Williamson Steven S. sold 9,648 shares for $1.60 per share. The transaction valued at 15,437 led to the insider holds 358,967 shares of the business.
Joshi Mehul sold 7,936 shares of LUNG for $12,698 on Sep 02 ’25. The Chief Financial Officer & PAO now owns 208,489 shares after completing the transaction at $1.60 per share. On Sep 02 ’25, another insider, Rose Geoffrey Beran, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 6,543 shares for $1.60 each. As a result, the insider received 10,469 and left with 379,788 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LUNG now has a Market Capitalization of 67232664 and an Enterprise Value of 47247664. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 1.12. Its current Enterprise Value per Revenue stands at 0.515 whereas that against EBITDA is -0.843.
Stock Price History:
The Beta on a monthly basis for LUNG is 0.23, which has changed by -0.7472868 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, LUNG has reached a high of $9.37, while it has fallen to a 52-week low of $1.31. The 50-Day Moving Average of the stock is -3.22%, while the 200-Day Moving Average is calculated to be -53.48%.
Shares Statistics:
For the past three months, LUNG has traded an average of 2.43M shares per day and 1151730 over the past ten days. A total of 41.25M shares are outstanding, with a floating share count of 38.38M. Insiders hold about 6.96% of the company’s shares, while institutions hold 77.73% stake in the company. Shares short for LUNG as of 1763078400 were 2036874 with a Short Ratio of 0.84, compared to 1760486400 on 1418511. Therefore, it implies a Short% of Shares Outstanding of 2036874 and a Short% of Float of 7.19.
Earnings Estimates
Pulmonx Corp (LUNG) is currently under the scrutiny of 6.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.3 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.43 and -$1.49 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.34, with 6.0 analysts recommending between -$1.22 and -$1.55.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $21.73M this quarter.It ranges from a high estimate of $23M to a low estimate of $21.1M. As of. The current estimate, Pulmonx Corp’s year-ago sales were $23.77MFor the next quarter, 6 analysts are estimating revenue of $22.65M. There is a high estimate of $24.64M for the next quarter, whereas the lowest estimate is $21.6M.
A total of 6 analysts have provided revenue estimates for LUNG’s current fiscal year. The highest revenue estimate was $90.9M, while the lowest revenue estimate was $89M, resulting in an average revenue estimate of $89.63M. In the same quarter a year ago, actual revenue was $83.79MBased on 6 analysts’ estimates, the company’s revenue will be $94.23M in the next fiscal year. The high estimate is $98.54M and the low estimate is $90.6M.
